Tag: Sanofi

The list price for a one-month supply of Dupixent is approximately $3,993, but this is rarely the final cost for patients. Understanding **how much does Dupixent cost for COPD** requires navigating insurance plans, assistance programs, and various discount options.

More than 25 brand-name and generic medications are currently approved for managing multiple sclerosis, with a diverse field of pharmaceutical companies dedicated to developing and manufacturing these vital treatments. This complex landscape is dominated by several major players who make MS drugs, alongside a growing number of smaller biotech firms.

In January 2017, a U.S. judge ordered Praluent off the market within 30 days, citing patent infringement, a decision that created significant uncertainty for patients and healthcare providers. However, this ban never took permanent effect in the United States, raising questions about the drug's true market status and **why was Praluent pulled from the market** in some regions more recently. The situation involves complex legal battles, evolving market strategies, and global supply chain challenges.

Cablivi (caplacizumab), a significant advancement in treating a rare blood-clotting disorder, was developed from a unique discovery in camel blood, leading to the creation of its innovative "nanobody" technology. Today, the global pharmaceutical company Sanofi is responsible for the manufacture and commercialization of caplacizumab.

First approved by the FDA in July 2009, the brand-name drug Multaq, or dronedarone, was developed and is manufactured by the pharmaceutical company Sanofi. However, with the approval of a generic equivalent in early 2024, other manufacturers have also entered the market, expanding the availability of this medication. This article provides a comprehensive overview of the manufacturers behind Multaq and its generic counterparts.

Affecting approximately 3,500 people in the US, Pompe disease is a rare genetic disorder treated by enzyme replacement therapies (ERTs). **What is Nexviazyme** and how does this second-generation treatment, developed by Sanofi, offer a new option for patients with the late-onset form of the disease?.

Affecting approximately 1 in every 57,000 people, late-onset Pompe disease is a rare genetic disorder caused by an enzyme deficiency. For many patients, the question, **'What is the drug Nexviazyme used for?'** is crucial. Nexviazyme is an enzyme replacement therapy specifically approved for treating late-onset Pompe disease in patients aged one year and older.

In December 2010, Johnson & Johnson recalled over 13 million packages of Rolaids due to contamination fears, causing the product to vanish from stores for years [1.3.1, 1.4.1]. This disappearance led many to ask, 'Why are Rolaids no longer available?', though the brand has since returned.

In February 2017, the FDA approved Xyzal Allergy 24HR for over-the-counter (OTC) use, leading many to wonder, 'Why was Xyzal discontinued?' [1.9.2, 1.9.3]. The truth is, it wasn't discontinued but rather made more accessible to consumers.